Drug‑Induced Cognitive Impairment: Evidence‑Based Facts

Spectrum of Cognitive Dysfunction

• Domain‑specific cognitive impairments (e.g., isolated memory or attention deficits) have been documented as a manifestation of drug‑induced cognitive impairment. 1

Implicated Medication Classes

• Anticholinergic agents—including antihistamines, overactive‑bladder drugs, and muscle relaxants—are associated with drug‑induced cognitive impairment. 3
• Chemotherapeutic agents are linked to the “chemobrain” syndrome, a form of drug‑induced cognitive impairment. 1

Prevalence in Specific Clinical Contexts

• In patients receiving chemotherapy for breast cancer, self‑reported cognitive impairment occurs in 17 %–78 % of individuals, while objective neurocognitive testing identifies impairment in approximately 33 % of patients. 2

Pathophysiological Mechanisms

• Disruption of the blood‑brain barrier with cytokine‑mediated inflammation contributes to drug‑induced cognitive impairment. 1
• Oxidative stress and impaired neuronal energy metabolism are implicated in the development of drug‑induced cognitive impairment. 1

Risk Factors

• Advanced age and childhood are identified as major risk factors for developing drug‑induced cognitive impairment. 3
• Polypharmacy and a high anticholinergic burden increase susceptibility to drug‑induced cognitive impairment. 3

Clinical Management Gaps

• No standardized management strategies or clinical practice guidelines currently exist for most forms of drug‑induced cognitive impairment. 2